Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

Recruiting

Phase 1

[177Lu]Lu-NeoBDose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

Sponsor:

Novartis Pharmaceuticals

Code:

NCT05739942

Conditions

Newly Diagnosed and Recurrent Glioblastoma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

[177Lu]Lu-NeoB

[68Ga]Ga-NeoB

Temozolomide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-13. This information was provided to ClinicalTrials.gov by Novartis Pharmaceuticals on 2025-08-22.